We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of The Chemours Company (NYSE: CC) (“Chemours” or the “Company”) concerning the Company’s suspension of its chief and senior executives pending an internal review over suspicious accounting and compensation practices.

On this news, the price of the Company’s shares fell more than 35% and the stock’s drop erased about $2 billion in market value at the share’s lowest price.  Analysts have correspondingly significantly reduced their stock price targets for the Company.

The internal review also prompted the Company to further delay the reporting of its fourth-quarter and full-year results without disclosing a new date. In submissions to the US Securities and Exchange Commission (“SEC”), Chemours provided estimates of its top line financials for 2023, and promised to file official, audited figures ‘as soon as practicable’.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients.  For more information about the firm, please go to: http://www.weisslaw.co